Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-ethoxycarbonyl-D-phe-pro-2(4-aminobutyl)hydrazine
- Development stage
- Unknown
- Modality
- Small Molecules, Peptides
01
Overview
1-ethoxycarbonyl-D-phe-pro-2(4-aminobutyl)hydrazine is an experimental small molecule dipeptide derivative, classified as a synthetic organic compound containing a sequence of two amino acids (D-phenylalanine and proline), with an ethoxycarbonyl group and a hydrazine moiety substituted with a 4-aminobutyl side chain. Its precise mechanism of action is not fully characterized in the public domain, but DrugBank lists prothrombin as its target, suggesting it may interact with or modulate this coagulation factor. The compound has been studied primarily in research settings and does not have established clinical indications or approvals[1].
02
Targets
F2 (Thrombin)
Beyond the preview
Go deeper on 1-ethoxycarbonyl-D-phe-pro-2(4-aminobutyl)hydrazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1-ethoxycarbonyl-D-phe-pro-2(4-aminobutyl)hydrazine.